Sensus Healthcare, Inc.

Equities

SRTS

US81728J1097

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-04-24 pm EDT 5-day change 1st Jan Change
3.28 USD -3.53% Intraday chart for Sensus Healthcare, Inc. +2.50% +38.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Sensus Healthcare, Inc., Q4 2023 Earnings Call, Feb 08, 2024
Sensus Healthcare, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (SRTS) SENSUS HEALTHCARE Posts Q4 Revenue $12.6M, vs. Street Est of $12.1M MT
Sensus Healthcare Announces Directors Changes CI
Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Sensus Healthcare, Inc. Appoints Michael Sardano as A Director, Effective February 1, 2024 CI
Tranche Update on Sensus Healthcare, Inc.'s Equity Buyback Plan announced on August 8, 2023. CI
Transcript : Sensus Healthcare, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (SRTS) SENSUS HEALTHCARE Posts Q3 Revenue $3.9M MT
Sensus Healthcare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego CI
Sensus Healthcare, Inc.(NasdaqCM:SRTS) dropped from S&P Global BMI Index CI
Sensus Healthcare, Inc. Enters into A Credit Agreement with Comerica Bank CI
Tranche Update on Sensus Healthcare, Inc.'s Equity Buyback Plan announced on March 9, 2022. CI
Sensus Healthcare Launches $3 Million Stock Buyback Program; Shares Surge 15% Midday MT
Sensus Healthcare, Inc. announces an Equity Buyback for $3 million worth of its shares. CI
Sensus Healthcare, Inc. authorizes a Buyback Plan. CI
HC Wainwright Adjusts Price Target on Sensus Healthcare to $8 From $10, Keeps Buy Rating MT
Earnings Flash (SRTS) SENSUS HEALTHCARE Reports Q2 Revenue $4.5M MT
Transcript : Sensus Healthcare, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Sensus Healthcare, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sensus Healthcare Completes Installation of Its First Srt System in Ireland CI
Sensus Healthcare Says SRT-100's Limited Study Shows Potential Effectiveness, Safety in Treating Cutaneous Mast Cell Tumors MT
Tranche Update on Sensus Healthcare, Inc.'s Equity Buyback Plan announced on March 9, 2022. CI
Sector Update: Health Care Stocks Slipping Late Thursday MT
Chart Sensus Healthcare, Inc.
More charts
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.28 USD
Average target price
7.5 USD
Spread / Average Target
+128.66%
Consensus